SEATTLE, Sept. 25, 2017 -- According to Coherent Market Insights, the Global Epistaxis Market (By drug type: vasoconstrictors, anesthetics, antibiotic ointments, cauterizing agents) was valued at US$ 130.0 million in 2016 and is projected to witness a CAGR of 5.7% over the forecast period (2017-2025). Increase in the concentration of harmful chemicals and gases in the atmospheric composition along with introduction of innovative treatment therapies is expected to be one of the major factors driving the growth of global epistaxis market over the foreseeable future.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/epistaxis-market-771
Key Trends and Analysis of the Epistaxis Market:
Recent studies have shown that epistaxis can be treated effectively even with simple medications. For instance, a case study published in the Journal of American Medical Association in September 2016, states that 121 patients with epistaxis sprayed either saline or standard medications for epistaxis such as estriol or tranexamic acid and surprisingly exhibited equal results leading to the discovery of a simple yet highly effective treatment for epistaxis emergency cases.
Request Sample Copy of the Business Report
Key players are involved in research and development of innovative epistaxis products. For instance, in 2016, Smith & Nephew launched a range of epistaxis devices with RAPID RHINO technology that has a blend of carboxymethylcellulose (CMC) within them exhibiting self-lubricating properties that provide gentle and even compression to the nasal area and helps in the quicker re-conformation of the nasal anatomy. Thus, the demand for epistaxis treatment is expected to witness dramatic growth in the near future, creating lucrative opportunities for the market players to grab more revenue with the introduction of cost-efficient and innovative devices.
Key Market Takeaways:
- The global epistaxis market is expected to expand at a CAGR of 5.7% during the forecast period (2016–2025), as there exists a huge market potential, especially in Asia Pacific, Middle East, and Africa
- Robust developments in cauterization procedures and rising number of patients suffering from hypertension are expected to drive the global epistaxis market
- Blunt trauma, nose picking, overly sensitive blood vessels in the nasal septum, common colds and flu, hypersensitivity, foreign body invasion into the nasal cavity, nasal tumors, anti-inflammatory medicines, consumption of anticoagulants, and snorting of cocaine are a few of the most commonly observed causes leading to epistaxis
- Some of the major players involved in the global epistaxis market include Smith & Nephew, Medline, Bristol-Myers Squibb Pharma Company, Ciron Drugs, and King Pharmaceutical, Inc.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]


Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 



